help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2007-0158
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lyons, L. S.
Right arrow Articles by Burnstein, K. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lyons, L. S.
Right arrow Articles by Burnstein, K. L.
Molecular Endocrinology 22 (3): 597-608
Copyright © 2008 by The Endocrine Society

Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer

Leah S. Lyons1, Shuyun Rao1, Wayne Balkan, Joanne Faysal, Carol A. Maiorino and Kerry L. Burnstein

Department of Molecular and Cellular Pharmacology (L.S.L., S.R., J.F., C.A.M., K.L.B.) and Department of Medicine (W.B.), University of Miami Miller School of Medicine, Miami, Florida 33136; and Geriatric Research Education and Clinical Center and Research Services (W.B.), Miami Veterans Affairs Medical Center, Miami, Florida 33125

Address all correspondence and requests for reprints to: Kerry L. Burnstein, 1600 North West Tenth Avenue (R-189), Miami, Florida 33136. E-mail: kburnste{at}miami.edu.

Prostate cancer invariably recurs after androgen deprivation therapy. Growth of this recurrent/androgen-independent form of prostate cancer may be due to increased androgen receptor (AR) transcriptional activity in the absence of androgen. This ligand-independent AR activation is promoted by some growth factors but the mechanism is not well understood. Vav3, a Rho guanosine triphosphatase guanine nucleotide exchange factor, which is activated by growth factors, is up-regulated in human prostate cancer. We show here that Vav3 levels increase during in vivo progression of prostate cancer to androgen independence. Vav3 strikingly enhanced growth factor activation of AR in the absence of androgen. Because Vav3 may be chronically activated in prostate cancer by growth factor receptors, we examined the effects of a constitutively active (Ca) form of Vav3 on AR transcriptional activity. Ca Vav3 caused nuclear localization and ligand-independent activation of AR via the Rho guanosine triphosphatase, Rac1. Ca Rac1 activation of AR occurred, in part, through MAPK/ERK signaling. Expression of active Rac1 conferred androgen-independent growth of prostate cancer cells in culture, soft agar, and mice. These findings suggest that Vav3/Rac 1 signaling is an important modulator of ligand-independent AR transcriptional activity in prostate cancer progression.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR
Coregulators:   VAV3
Ligands:   Bicalutamide  |  R1881






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society